Powered by

Novartis to acquire neuroscience firm Cadent Therapeutics for up to $770m

Dec 17, 2020 - Marketline Newswire
Mergers and Acquisitions

Novartis has entered into a definitive agreement to acquire all of the outstanding capital stock of US-based neuroscience company Cadent Therapeutics for a total potential consideration of up to $770m.

Under the deal, Cadent will receive an upfront payment of $210m and is eligible for milestone payments of up to $560m. With this acquisition, Novartis will gain complete rights to Cadent's neuroscience portfolio, including its NMDAr programme, which features two clinical programmes - CAD-930...